Letters

I read Myrna E. Watanabe's article on sponsored clinical research in the managed care setting (The Scientist, June 24, 1996, page 1) with great interest. It is clear that clinical research of all sorts eventually will need to be conducted by and in managed care organizations (MCOs). After all, traditional settings for such research are disappearing as managed care is becoming a major, if not the dominant, modality of health care delivery. Moreover, assurance of research validity will require th

Written byGary Steinman
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

I read Myrna E. Watanabe's article on sponsored clinical research in the managed care setting (The Scientist, June 24, 1996, page 1) with great interest. It is clear that clinical research of all sorts eventually will need to be conducted by and in managed care organizations (MCOs). After all, traditional settings for such research are disappearing as managed care is becoming a major, if not the dominant, modality of health care delivery. Moreover, assurance of research validity will require that a representative amount of clinical research be adapted to MCO requirements and conducted in the managed care environment.

p It seems to me that the societal covenant that has supported clinical research and improved health care over the years has eroded as the structure, settings, and players of our health care system have changed. A new system of research resources, capabilities, obligations, and involvements must emerge. Hopefully, it will evolve ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies